NO980195L - Cyklosporinderivater med anti-HIV-effekt - Google Patents
Cyklosporinderivater med anti-HIV-effektInfo
- Publication number
- NO980195L NO980195L NO980195A NO980195A NO980195L NO 980195 L NO980195 L NO 980195L NO 980195 A NO980195 A NO 980195A NO 980195 A NO980195 A NO 980195A NO 980195 L NO980195 L NO 980195L
- Authority
- NO
- Norway
- Prior art keywords
- stands
- amino
- valine
- branched
- alkyl
- Prior art date
Links
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical class CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 title 1
- 230000036436 anti-hiv Effects 0.000 title 1
- 230000000694 effects Effects 0.000 title 1
- 235000001014 amino acid Nutrition 0.000 abstract 3
- 150000001413 amino acids Chemical class 0.000 abstract 3
- 241000725303 Human immunodeficiency virus Species 0.000 abstract 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 abstract 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 abstract 2
- 125000004423 acyloxy group Chemical group 0.000 abstract 2
- 125000003342 alkenyl group Chemical group 0.000 abstract 2
- 125000006193 alkinyl group Chemical group 0.000 abstract 2
- 125000003282 alkyl amino group Chemical group 0.000 abstract 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 2
- 125000004663 dialkyl amino group Chemical group 0.000 abstract 2
- 125000001153 fluoro group Chemical group F* 0.000 abstract 2
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 150000002367 halogens Chemical class 0.000 abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 150000002431 hydrogen Chemical class 0.000 abstract 2
- 239000001257 hydrogen Substances 0.000 abstract 2
- -1 hydroxy, amino Chemical group 0.000 abstract 2
- 239000004474 valine Substances 0.000 abstract 2
- NHOZVNREBGDUSQ-ZETCQYMHSA-N (2s)-2-(acetyloxyamino)-4-methylpentanoic acid Chemical compound CC(C)C[C@@H](C(O)=O)NOC(C)=O NHOZVNREBGDUSQ-ZETCQYMHSA-N 0.000 abstract 1
- QWCKQJZIFLGMSD-UHFFFAOYSA-N 2-Aminobutanoic acid Natural products CCC(N)C(O)=O QWCKQJZIFLGMSD-UHFFFAOYSA-N 0.000 abstract 1
- 102000001189 Cyclic Peptides Human genes 0.000 abstract 1
- 108010069514 Cyclic Peptides Proteins 0.000 abstract 1
- MTCFGRXMJLQNBG-UWTATZPHSA-N D-Serine Chemical compound OC[C@@H](N)C(O)=O MTCFGRXMJLQNBG-UWTATZPHSA-N 0.000 abstract 1
- 229930195711 D-Serine Natural products 0.000 abstract 1
- QNAYBMKLOCPYGJ-UWTATZPHSA-N D-alanine Chemical compound C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 abstract 1
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 abstract 1
- QWCKQJZIFLGMSD-GSVOUGTGSA-N D-alpha-aminobutyric acid Chemical compound CC[C@@H](N)C(O)=O QWCKQJZIFLGMSD-GSVOUGTGSA-N 0.000 abstract 1
- SNDPXSYFESPGGJ-BYPYZUCNSA-N L-2-aminopentanoic acid Chemical compound CCC[C@H](N)C(O)=O SNDPXSYFESPGGJ-BYPYZUCNSA-N 0.000 abstract 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 abstract 1
- SNDPXSYFESPGGJ-UHFFFAOYSA-N L-norVal-OH Natural products CCCC(N)C(O)=O SNDPXSYFESPGGJ-UHFFFAOYSA-N 0.000 abstract 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 abstract 1
- AKCRVYNORCOYQT-YFKPBYRVSA-N N-methyl-L-valine Chemical compound CN[C@@H](C(C)C)C(O)=O AKCRVYNORCOYQT-YFKPBYRVSA-N 0.000 abstract 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 abstract 1
- 239000004473 Threonine Substances 0.000 abstract 1
- 125000003668 acetyloxy group Chemical group [H]C([H])([H])C(=O)O[*] 0.000 abstract 1
- 235000004279 alanine Nutrition 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 125000004744 butyloxycarbonyl group Chemical group 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- LOTBYPQQWICYBB-UHFFFAOYSA-N methyl n-hexyl-n-[2-(hexylamino)ethyl]carbamate Chemical compound CCCCCCNCCN(C(=O)OC)CCCCCC LOTBYPQQWICYBB-UHFFFAOYSA-N 0.000 abstract 1
- XJODGRWDFZVTKW-ZCFIWIBFSA-N n-methylleucine Chemical compound CN[C@@H](C(O)=O)CC(C)C XJODGRWDFZVTKW-ZCFIWIBFSA-N 0.000 abstract 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/64—Cyclic peptides containing only normal peptide links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/64—Cyclic peptides containing only normal peptide links
- C07K7/645—Cyclosporins; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Nye cykliske peptider med den generelle formel (I), hvor bokstavene A til K står for rester av de følgende aminosyrer: B.C.D.E.F K.J.I.H.G. (D hvor bokstavene A til K står for rester ifølge aminosyrene: A står for et substituert homotreonin med den generelle formel R!CH2 CH(CH3)-CH(OH)-CH(NHCH3)-COOH (II) B C hvor R = hvor RI står for n-propyl eller propenyl og dobbelbindingen fortrinnsvis er transkonfigurert, står for alfa-aminosmørsyre, valin, norvalin eller treonin, står for en (D)-aminosyre med den generelle formel CH3NH-CH(R)-COOH III C2-C(;-alkyl, alkenyl, alkinyl, rettkjedet eller forgrenet, hvor disse guppene også kan være substituert med hydroksy, amino, Ci-C4-alkylamino, Ci-C4-dialkyl- amino, alkoksy eller acyloksy, COOR2, CONHR2, hvor R2 = Ci-C^alkyl, som kan være rettkjedet eller for- grenet, X-R3, hvor X = O, S og R3 = Ci-C4-alkyl, alkenyl, alkinyl, rettkjedet eller for- grenet og hvor, når X = S, kan R3 også være aryl eller heteroaryl, halogen, fortrinnsvis fluor, cyano, CHR4R5, hvor R4 = hydrogen, metyl, etyl, fenyl, og R 5 = hydrogen, hydroksy, halogen, fortrinnsvis fluor, foruten amino, Ci-C4-alkylamino, Ci-C4-dialkyl- amino, acyloksy, fortrinnsvis acetyloksy, videre tert-butoksykarbonyl-amino- etoksy-etoksy-acetyloksy, alkoksykarbonyl, fortrinnsvis butoksykarbonyl, D står for N-metyl-gamma-hydroksyleucin eller N-metyl-gamma-acetyloksyleucin, E står for valin, F, I og J står alltid for N-metylleucin, G står for alanin, H står for (D)-alanin, (D)-serin og K står for N-metyl-valin, deres fremstilling og anvendelse for behandling og forebygging av infeksjoner av humanimmunsviktvirus (HIV).
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP95111162 | 1995-07-17 | ||
PCT/EP1996/003129 WO1997004005A2 (de) | 1995-07-17 | 1996-07-17 | Cyclosporin-derivate mit anti-hiv-wirkung |
Publications (2)
Publication Number | Publication Date |
---|---|
NO980195L true NO980195L (no) | 1998-01-15 |
NO980195D0 NO980195D0 (no) | 1998-01-15 |
Family
ID=8219438
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO980195A NO980195D0 (no) | 1995-07-17 | 1998-01-15 | Cyklosporinderivater med anti-HIV-effekt |
Country Status (17)
Country | Link |
---|---|
US (1) | US5948884A (no) |
EP (1) | EP0842191B1 (no) |
JP (1) | JP3920919B2 (no) |
KR (1) | KR100441220B1 (no) |
CN (1) | CN1141317C (no) |
AT (1) | ATE209216T1 (no) |
AU (1) | AU722858B2 (no) |
BR (1) | BR9609795A (no) |
CA (1) | CA2226880C (no) |
CZ (1) | CZ290754B6 (no) |
DE (1) | DE59608274D1 (no) |
HU (1) | HUP9900405A3 (no) |
IL (1) | IL122754A (no) |
NO (1) | NO980195D0 (no) |
NZ (1) | NZ315324A (no) |
PL (1) | PL324531A1 (no) |
WO (1) | WO1997004005A2 (no) |
Families Citing this family (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2757521B1 (fr) * | 1996-12-24 | 1999-01-29 | Rhone Poulenc Rorer Sa | Nouveaux derives de cyclosporine, leur preparation et les compositions pharmaceutiques qui les contiennent |
FR2757520B1 (fr) * | 1996-12-24 | 1999-01-29 | Rhone Poulenc Rorer Sa | Derive de cyclosporine, sa preparation et les compositions pharmaceutiques qui le contiennent |
FR2757522B1 (fr) * | 1996-12-24 | 1999-01-29 | Rhone Poulenc Rorer Sa | Derives de cyclosporine, leur preparation et les compositions pharmaceutiques qui les contiennent |
FR2762843B1 (fr) * | 1997-04-30 | 1999-12-10 | Rhone Poulenc Rorer Sa | Nouveaux derives de cyclosporine, leur preparation et les compositions pharmaceutiques qui les contiennent |
US6270957B1 (en) | 1997-08-26 | 2001-08-07 | Wisconsin Alumni Research Foundation | Non-Imuunosuppressive cyclosporins and their use in the prevention and treatment of HIV infection |
US6316405B1 (en) * | 1997-08-26 | 2001-11-13 | Wisconsin Alumni Research Foundation | Cyclosporin a conjugates and uses therefor |
FR2772768B1 (fr) * | 1997-12-19 | 2000-01-14 | Rhone Poulenc Rorer Sa | Nouveau procede de preparation de derives de cyclosporine |
WO1999065933A1 (en) * | 1998-06-12 | 1999-12-23 | C-Chem Ag | Novel cyclosporins |
DK1091975T3 (da) | 1998-07-01 | 2006-04-18 | Debiopharm Sa | Ny cyclosporin med forbedret aktivitetsprofil |
KR100465012B1 (ko) * | 2001-05-11 | 2005-01-13 | 주식회사 엘지생활건강 | 모발 성장 효과를 갖는 사이클로스포린 3 위치 유도체를유효성분으로 하는 모발 성장 촉진제 |
PT1436321E (pt) | 2001-10-19 | 2006-10-31 | Isotechnika Inc | Sintese de analogos de ciclosporina |
US7108988B2 (en) | 2001-11-02 | 2006-09-19 | The J. David Gladstone Institutes | Methods of identifying agents for inhibiting lentivirus replication |
US6987090B2 (en) * | 2002-05-09 | 2006-01-17 | Lg Household & Health Care Ltd. | Use of 3-position cyclosporin derivatives for hair growth |
AU2004222306A1 (en) * | 2003-03-17 | 2004-09-30 | Albany Molecular Research, Inc. | Novel cyclosporins |
EP1804823A4 (en) * | 2004-09-29 | 2010-06-09 | Amr Technology Inc | NEW CYCLOSPORIN ANALOGUE AND ITS PHARMACEUTICAL APPLICATIONS |
US7196161B2 (en) * | 2004-10-01 | 2007-03-27 | Scynexis Inc. | 3-ether and 3-thioether substituted cyclosporin derivatives for the treatment and prevention of hepatitis C infection |
KR101309409B1 (ko) * | 2004-10-01 | 2013-09-23 | 싸이넥시스, 인크. | C형 간염 바이러스 감염의 치료 및 예방을 위한 3-에테르및 3-티오에테르 치환된 시클로스포린 유도체 |
US7361636B2 (en) * | 2004-10-06 | 2008-04-22 | Amr Technology, Inc. | Cyclosporin alkynes and their utility as pharmaceutical agents |
JP5322647B2 (ja) * | 2005-09-30 | 2013-10-23 | スシネキス インク | ウイルス感染の治療及び予防のためのシクロスポリンaのアリールアルキル及びヘテロアリールアルキル誘導体 |
AU2006299426B2 (en) * | 2005-09-30 | 2012-07-26 | Scynexis, Inc. | Methods and pharmaceutical compositions for the treatment and prevention of hepatitis C infection |
US7696166B2 (en) * | 2006-03-28 | 2010-04-13 | Albany Molecular Research, Inc. | Use of cyclosporin alkyne/alkene analogues for preventing or treating viral-induced disorders |
US7696165B2 (en) * | 2006-03-28 | 2010-04-13 | Albany Molecular Research, Inc. | Use of cyclosporin alkyne analogues for preventing or treating viral-induced disorders |
US20070232532A1 (en) * | 2006-03-28 | 2007-10-04 | Amr Technology, Inc. | Use of cyclosporin alkene analogues for preventing or treating viral-induced disorders |
ATE502633T1 (de) | 2006-05-19 | 2011-04-15 | Scynexis Inc | Cyclosporins zur behandlung und vorbeugung von augenerkrankungen |
EP2027761A1 (fr) * | 2006-06-02 | 2009-02-25 | Claude Annie Perrichon | Gestion des electrons actifs |
WO2008069917A2 (en) | 2006-11-20 | 2008-06-12 | Scynexis, Inc. | Novel cyclic peptides |
US20080255038A1 (en) * | 2007-04-11 | 2008-10-16 | Samuel Earl Hopkins | Pharmaceutical compositions |
US20090306033A1 (en) * | 2008-06-06 | 2009-12-10 | Keqiang Li | Novel cyclic peptides |
WO2010002428A2 (en) * | 2008-06-06 | 2010-01-07 | Scynexis, Inc. | Novel macrocyclic peptides |
DE102008060549A1 (de) | 2008-12-04 | 2010-06-10 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Wirkstoff-Peptid-Konstrukt zur extrazellulären Anreicherung |
AU2009334790B2 (en) * | 2008-12-31 | 2016-09-08 | Scynexis, Inc. | Derivatives of cyclosporin A |
CN101874902B (zh) * | 2009-06-19 | 2013-04-03 | 清华大学 | 一种用于人工椎间盘髓核假体材料的制备方法 |
CN102834409A (zh) * | 2009-12-30 | 2012-12-19 | 西尼克斯公司 | 环孢菌素类似物 |
CN103153330B (zh) | 2010-08-12 | 2017-08-18 | 美国科技环球有限公司 | 新的环孢霉素衍生物在病毒感染的治疗和预防中的应用 |
DK2646043T3 (da) * | 2010-12-03 | 2017-05-22 | S&T Global Inc | Hidtil ukendte cyclosporinderivater til behandling og forebyggelse af en virusinfektion |
US9890198B2 (en) | 2010-12-03 | 2018-02-13 | S&T Global Inc. | Cyclosporin derivatives and uses thereof |
AU2011342284C1 (en) | 2010-12-15 | 2017-07-13 | Contravir Pharmaceuticals, Inc. | Cyclosporine analogue molecules modified at amino acid 1 and 3 |
EP2705856A1 (en) | 2012-09-07 | 2014-03-12 | Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. | Compounds for the treatment of neurodegenerative disorders |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0194972B1 (en) * | 1985-03-11 | 1992-07-29 | Sandoz Ag | Novel cyclosporins |
US5122511A (en) * | 1990-02-27 | 1992-06-16 | Merck & Co., Inc. | Immunosuppressive cyclosporin analogs with modified amino acids at position-8 |
EP0484281B2 (en) * | 1990-11-02 | 2000-11-22 | Novartis AG | Cyclosporins |
-
1996
- 1996-07-17 IL IL12275496A patent/IL122754A/en not_active IP Right Cessation
- 1996-07-17 US US08/009,815 patent/US5948884A/en not_active Expired - Lifetime
- 1996-07-17 BR BR9609795A patent/BR9609795A/pt not_active Application Discontinuation
- 1996-07-17 PL PL96324531A patent/PL324531A1/xx unknown
- 1996-07-17 DE DE59608274T patent/DE59608274D1/de not_active Expired - Lifetime
- 1996-07-17 CN CNB96196264XA patent/CN1141317C/zh not_active Expired - Fee Related
- 1996-07-17 AT AT96927023T patent/ATE209216T1/de not_active IP Right Cessation
- 1996-07-17 NZ NZ315324A patent/NZ315324A/en not_active IP Right Cessation
- 1996-07-17 KR KR10-1998-0700269A patent/KR100441220B1/ko not_active IP Right Cessation
- 1996-07-17 EP EP96927023A patent/EP0842191B1/de not_active Expired - Lifetime
- 1996-07-17 HU HU9900405A patent/HUP9900405A3/hu unknown
- 1996-07-17 WO PCT/EP1996/003129 patent/WO1997004005A2/de active IP Right Grant
- 1996-07-17 AU AU67001/96A patent/AU722858B2/en not_active Ceased
- 1996-07-17 CZ CZ199851A patent/CZ290754B6/cs not_active IP Right Cessation
- 1996-07-17 JP JP50628797A patent/JP3920919B2/ja not_active Expired - Fee Related
- 1996-07-17 CA CA002226880A patent/CA2226880C/en not_active Expired - Fee Related
-
1998
- 1998-01-15 NO NO980195A patent/NO980195D0/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
HUP9900405A2 (hu) | 1999-06-28 |
AU722858B2 (en) | 2000-08-10 |
AU6700196A (en) | 1997-02-18 |
CA2226880A1 (en) | 1997-02-06 |
EP0842191A2 (de) | 1998-05-20 |
CN1141317C (zh) | 2004-03-10 |
JP2000502320A (ja) | 2000-02-29 |
CN1192750A (zh) | 1998-09-09 |
NO980195D0 (no) | 1998-01-15 |
CA2226880C (en) | 2007-04-10 |
WO1997004005A2 (de) | 1997-02-06 |
KR100441220B1 (ko) | 2005-02-24 |
BR9609795A (pt) | 1999-03-16 |
KR19990028967A (ko) | 1999-04-15 |
PL324531A1 (en) | 1998-06-08 |
NZ315324A (en) | 1999-10-28 |
MX9800477A (es) | 1998-09-30 |
DE59608274D1 (de) | 2002-01-03 |
EP0842191B1 (de) | 2001-11-21 |
CZ5198A3 (cs) | 1998-04-15 |
US5948884A (en) | 1999-09-07 |
WO1997004005A3 (de) | 1997-02-27 |
IL122754A0 (en) | 1998-08-16 |
CZ290754B6 (cs) | 2002-10-16 |
JP3920919B2 (ja) | 2007-05-30 |
HUP9900405A3 (en) | 2001-04-28 |
ATE209216T1 (de) | 2001-12-15 |
IL122754A (en) | 2001-10-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO980195L (no) | Cyklosporinderivater med anti-HIV-effekt | |
DE60119145D1 (de) | Ein antigen und ein adjuvans-peptid enthaltende impfstoffzusammensetzung | |
PE108898A1 (es) | Derivados 6,5-heterobiciclicos sustituidos | |
HRP20030139B8 (hr) | Peptidomimetiäśki inhibitori proteaza | |
IS7533A (is) | Lifrarbólgu C-veirutálmar | |
EP1042363A1 (fr) | Nouveaux immunogenes anti-hiv (toxoides), procedes de preparation et application a la prevention et au traitement du sida | |
HUP9800518A2 (hu) | Heterogyűrűs-karbonil-aminosav-(hidroxi-etil-amino)-szulfonamid retrovírus proteáz inhibitorok | |
DE69033521T2 (de) | Verwendung von arginin als immunstimulator | |
ATE2958T1 (de) | Muramyldipeptid-derivate, verfahren zur herstellung dieser verbindungen und diese enthaltende pharmazeutische zusammensetzungen. | |
CY1107990T1 (el) | Τριπεπτιδια και παραγωγα τριπεπτιδιων για τη θepαπεια νευροεκφυλιστικων ασθενειων | |
NO20031671L (no) | Dioksolananaloger for forbedret intercellulaer avlevering | |
CY1110487T1 (el) | Χρηση της lh σε ελεγχομενη υπερδιεγερση των ωοθηκων | |
RU2003133742A (ru) | Модифицированный циклоспорин, который можно использовать в качестве пролекарства, и его применение | |
CA2248630A1 (en) | Synthetic peptides and pseudopeptides having osteogenic activity and pharmaceutical compositions containing the same | |
FR2831165B1 (fr) | Nouveaux derives du norbornane et du norbornene, leur utilisation et produits parfumes les contenant | |
NO942360L (no) | Vaksine og polypeptider som er nyttige for denne | |
HUP9801680A2 (hu) | Peptidek és ezeket tartalmazó gyógyászati készítmények autoimmun betegségek kezelésére | |
EA202192607A1 (ru) | Композиции и способы для лечения глазного заболевания | |
KR890700131A (ko) | 신규 화합물 | |
KR930001927A (ko) | 항혈소판 작용을 갖는 히루딘 동족체 | |
ATE285244T1 (de) | Tripeptide und deren derivate zur behandlung von postläsionalen krankheiten des nervensystems | |
HUP9904011A2 (hu) | Dipeptidszármazék új sói és alkalmazásuk gyógyszerkészítmények előállítására | |
ATE310529T1 (de) | Tripeptidderivate zur behandlung von postläsionalen krankheiten des nervensystems | |
NO931091L (no) | Analoger av sykloinopeptid a og anvendelse derav |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |